New hope for aggressive brain cancer: experimental drug combo tested
NCT ID NCT07538128
First seen Apr 23, 2026 · Last updated May 24, 2026 · Updated 6 times
Summary
This early-stage study tests a new drug called YSCH-01, alone or with another drug (atezolizumab), in 10 people whose glioblastoma (a severe brain cancer) has returned. The main goal is to check safety and see if the treatment helps patients live at least one year longer. Participants must be in fairly good health and have a tumor of a certain size.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital
RECRUITINGShanghai, Shanghai Municipality, 200040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.